Theramx Inc.

Creating Value for the World


2022.04.04: Medical Today - Theramx, Topical Skin Adhesive for epidermal bonding accelerated global business expansion in the US and Indonesia
Writer 관리자 Date 2022.04.14 Hit 127
File file  file  



Theramx, 'Skinstitch LLC' of the United States, and 'PT. Prima Centra Medika citra' of Indonesia. 

It was announced on the 4th that it had completed a distribution supply contract.


'EG-Q Bond', a bioadhesive for epidermal bonding, released through research and development by Theramx, is a medical device that joins the skin without the use of a separate suture. It compensates for the shortcomings of existing mechanical bonding materials.


This contract is the largest of its export contracts with the US for $2,250,000 and Indonesia for $750,000 for three years. In addition, the company plans to continuously expand its global business through strengthening partnerships and new contracts with leading companies located in Spain, UAE, Saudi Arabia and Singapore, which are already exporting.


According to this domestic and overseas market expansion, facility expansion and process automation of the production and manufacturing facility (GMP) are in progress until May of this year to improve productivity, and continuous investment and R&D are in progress to grow into a substantial bio platform company. company's statement.


An official said, "We started to enter the European market last year, and this year we succeeded in entering the US and Indonesia markets, and we are currently negotiating an export contract with a Middle East Asian company. In addition, we are expanding our product lineup in line with the global market trend for bioadhesives, and in the second quarter of this year, new products with improved containers and solutions with up to three times the amount of solutions will be launched in consideration of user convenience.”


View Article